Anixa Biosciences Inc. Advances Ovarian Cancer CAR‑T Trial and Announces $200 M Shelf Offer

SAN JOSE, CA – 10 September 2025 – Anixa Biosciences Inc. (NASDAQ: ANIX), a biotechnology company focused on cancer diagnostics and therapeutics, reported a significant milestone in its ovarian cancer program and filed a new mixed‑securities shelf offering.

1. Clinical Milestone: Completion of Fourth Cohort in Phase 1 CAR‑T Trial

Anixa announced that it has completed dosing of the fourth cohort in its Phase 1 clinical trial (NCT05316129) evaluating a follicle‑stimulating hormone receptor (FSHR)-targeted CAR‑T/CER‑T therapy for recurrent ovarian cancer. The study is being conducted in partnership with Moffitt Cancer Center.

Key points from the announcement:

  • Safety profile: No dose‑limiting toxicities, cytokine release syndrome, or immune effector cell‑associated neurotoxicity were observed in the four cohorts.
  • Efficacy signals: Multiple patients surpassed the median expected survival for this disease setting.
  • Next step: The fifth cohort is expected to commence following a routine 30‑day safety verification.

The company highlighted that the safety data support continued expansion of the trial and that the dosing strategy aligns with regulatory expectations for early‑phase cellular therapies.

2. Capital Raise: $200 M Mixed‑Securities Shelf Offering

On 10 September 2025, Anixa filed a new shelf offering that allows the company to issue up to $200 million of new securities. The offering is structured as a mixed‑securities offering, providing flexibility to issue common stock, senior unsecured notes, or other instruments as deemed appropriate by management.

Key details:

  • Purpose: The proceeds are intended to fund ongoing clinical development, support regulatory activities, and provide working capital.
  • Flexibility: The mixed‑securities nature enables the company to tailor the mix of equity and debt to market conditions and strategic needs.
  • Regulatory filing: The filing was made with the Securities and Exchange Commission (SEC) and is subject to standard SEC review and compliance requirements.

3. Market Context

  • Stock price: As of 8 September 2025, Anixa’s shares closed at $2.98, below its 52‑week low of $2.07 but near its 52‑week high of $4.20.
  • Market capitalization: Approximately $95.99 million USD.
  • Investor interest: The company was highlighted in a MarketBeat feature on 9 September 2025 among “under‑the‑radar” biotech stocks under $5 that could see significant upside, alongside HOTH and SILO.

4. Company Background

Anixa Biosciences Inc. specializes in developing diagnostics and therapeutics for detecting and treating cancer. The company operates primarily in the United States and lists on the Nasdaq exchange. Founded in 1987, Anixa has pursued a portfolio of programs targeting various oncological indications, with a recent focus on FSHR‑targeted cellular therapies.

For further information, visit www.anixa.com .